Next Article in Journal
Prevalence and Selected Sociodemographic of Movement Behaviors in Schoolchildren from Low- and Middle-Income Families in Nanjing, China: A Cross-Sectional Questionnaire Survey
Next Article in Special Issue
Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond
Previous Article in Journal / Special Issue
Advances in Pediatric Acute Promyelocytic Leukemia
Open AccessReview

New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)

by Jing Chen 1,* and Chana L. Glasser 2,*
Division of Pediatric Hematology/Oncology, Hackensack University Medical Center, Hackensack, NJ 07601, USA
Division of Pediatric Hematology/Oncology, NYU Winthrop Hospital, Mineola, NY 11501, USA
Authors to whom correspondence should be addressed.
Children 2020, 7(2), 12;
Received: 16 December 2019 / Revised: 30 January 2020 / Accepted: 1 February 2020 / Published: 10 February 2020
The relapse rate for children with acute myeloid leukemia (AML) remains high despite advancements in risk classification, multi-agent chemotherapy intensification, stem cell transplantation, and supportive care guidelines. Prognosis for this subgroup of children with relapsed/refractory AML remains poor. It is well known that the ceiling of chemotherapy intensification has been reached, limited by acute and chronic toxicity, necessitating alternative treatment approaches. In the last several years, our improved understanding of disease biology and critical molecular pathways in AML has yielded a variety of new drugs to target these specific pathways. This review provides a summary of antibody drug conjugates (ADCs), small molecule inhibitors, and tyrosine kinase inhibitors with an emphasis on those that are currently under clinical evaluation or soon to open in early phase trials for children with relapsed/refractory AML.
Keywords: acute myeloid leukemia; antibody drug conjugate acute myeloid leukemia; antibody drug conjugate
MDPI and ACS Style

Chen, J.; Glasser, C.L. New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML). Children 2020, 7, 12.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop